Search research articles
Contact Us
Filters
Showing results (61-70 of 115) with videos related to
Page
of 12
Sort By:
CNS Drugs
|
December 12, 2018
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
Jeremy Hobart, Tjalf Ziemssen, Peter Feys, et al.
CNS Drugs
|
September 6, 2024
Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study
Daniel Kreiter, Tomas Kalincik, Raymond Hupperts, et al.
Journal of Neuroimmunology
|
June 11, 2013
Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients
Judith Fraussen, Kathleen Vrolix, Nele Claes, et al.
Therapeutic Advances in Neurological Disorders
|
October 12, 2018
Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
Philipp Albrecht, Ingrid Kristine Bjørnå, David Brassat, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
June 15, 2016
Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study
Ilya Kister, Tim Spelman, Raed Alroughani, et al.
Multiple Sclerosis and Related Disorders
|
February 15, 2022
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
Bruno Brochet, Raymond Hupperts, Dawn Langdon, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 18, 2023
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
Bruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, et al.
Neurology
|
May 14, 2017
Evaluating the safety of β-interferons in MS: A series of nested case-control studies
Hilda J I de Jong, Elaine Kingwell, Afsaneh Shirani, et al.
Journal of Neurochemistry
|
September 11, 2012
Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome
Myrthe Rouwette, Klaartje Somers, Cindy Govarts, et al.
Therapeutic Advances in Neurological Disorders
|
January 31, 2022
Smouldering multiple sclerosis: the 'real MS'
Gavin Giovannoni, Veronica Popescu, Jens Wuerfel, et al.
Page
of 12
Search research articles
Search
Showing results (61-70 of 115) with videos related to
Sort By:
Page
of 12
CNS Drugs
|
December 12, 2018
Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine
Jeremy Hobart, Tjalf Ziemssen, Peter Feys, et al.
CNS Drugs
|
September 6, 2024
Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study
Daniel Kreiter, Tomas Kalincik, Raymond Hupperts, et al.
Journal of Neuroimmunology
|
June 11, 2013
Autoantigen induced clonal expansion in immortalized B cells from the peripheral blood of multiple sclerosis patients
Judith Fraussen, Kathleen Vrolix, Nele Claes, et al.
Therapeutic Advances in Neurological Disorders
|
October 12, 2018
Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting
Philipp Albrecht, Ingrid Kristine Bjørnå, David Brassat, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
June 15, 2016
Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study
Ilya Kister, Tim Spelman, Raed Alroughani, et al.
Multiple Sclerosis and Related Disorders
|
February 15, 2022
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
Bruno Brochet, Raymond Hupperts, Dawn Langdon, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)
|
November 18, 2023
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
Bruno Brochet, Alessandra Solari, Jeannette Lechner-Scott, et al.
Neurology
|
May 14, 2017
Evaluating the safety of β-interferons in MS: A series of nested case-control studies
Hilda J I de Jong, Elaine Kingwell, Afsaneh Shirani, et al.
Journal of Neurochemistry
|
September 11, 2012
Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome
Myrthe Rouwette, Klaartje Somers, Cindy Govarts, et al.
Therapeutic Advances in Neurological Disorders
|
January 31, 2022
Smouldering multiple sclerosis: the 'real MS'
Gavin Giovannoni, Veronica Popescu, Jens Wuerfel, et al.
Page
of 12